

ASX Announcement

18 February 2026

1H FY26 Results and Investor Webinar Notification

Genetic Signatures [ASX:GSS] (“GSS” or “the Company”), a global molecular diagnostics company will release its 1H FY26 results on Thursday, 26 February 2026.

The Company will host an investor webinar at 10:00am (AEDT) on Thursday, 26 February 2026 where Chair, Caroline Waldron and Interim Managing Director, Anne Lockwood will discuss the results.

The Company’s outgoing CEO, Allison Rossiter will attend the call and be available for the Q&A session alongside Directors, Jen Harry and Mike Aicher.

The in-coming CEO Maria Halasz will attend the call for an introduction to shareholders at the end of the session.

To register for the investor webinar please visit the link below:

[1H FY26 Investor Webinar](#)

– END –

Announcement authorised for release by the Board of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us:

Daniel Ireland

Investor Relations

daniel.ireland@datair.com.au

0428 607 884

About Genetic Signatures Limited:

Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious diseases, using patented 3base® technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures’ unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.